These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 26081142)

  • 1. The Role of TDP-43 in Alzheimer's Disease.
    Chang XL; Tan MS; Tan L; Yu JT
    Mol Neurobiol; 2016 Jul; 53(5):3349-3359. PubMed ID: 26081142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies.
    Higashi S; Iseki E; Yamamoto R; Minegishi M; Hino H; Fujisawa K; Togo T; Katsuse O; Uchikado H; Furukawa Y; Kosaka K; Arai H
    Brain Res; 2007 Dec; 1184():284-94. PubMed ID: 17963732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. β-amyloid triggers ALS-associated TDP-43 pathology in AD models.
    Herman AM; Khandelwal PJ; Stanczyk BB; Rebeck GW; Moussa CE
    Brain Res; 2011 Apr; 1386():191-9. PubMed ID: 21376022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TDP-43 in aging and Alzheimer's disease - a review.
    Wilson AC; Dugger BN; Dickson DW; Wang DS
    Int J Clin Exp Pathol; 2011 Jan; 4(2):147-55. PubMed ID: 21326809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional distribution of TDP-43 inclusions in Alzheimer disease (AD) brains: their relation to AD common pathology.
    Kadokura A; Yamazaki T; Lemere CA; Takatama M; Okamoto K
    Neuropathology; 2009 Oct; 29(5):566-73. PubMed ID: 19422539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease.
    Amador-Ortiz C; Lin WL; Ahmed Z; Personett D; Davies P; Duara R; Graff-Radford NR; Hutton ML; Dickson DW
    Ann Neurol; 2007 May; 61(5):435-45. PubMed ID: 17469117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct molecular patterns of TDP-43 pathology in Alzheimer's disease: relationship with clinical phenotypes.
    Tomé SO; Vandenberghe R; Ospitalieri S; Van Schoor E; Tousseyn T; Otto M; von Arnim CAF; Thal DR
    Acta Neuropathol Commun; 2020 Apr; 8(1):61. PubMed ID: 32349792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody 9D5 recognizes oligomeric pyroglutamate amyloid-β in a fraction of amyloid-β deposits in Alzheimer's disease without cross-reactivity with other protein aggregates.
    Venkataramani V; Wirths O; Budka H; Härtig W; Kovacs GG; Bayer TA
    J Alzheimers Dis; 2012; 29(2):361-71. PubMed ID: 22232007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TDP-43 Pathology in Alzheimer's Disease.
    Meneses A; Koga S; O'Leary J; Dickson DW; Bu G; Zhao N
    Mol Neurodegener; 2021 Dec; 16(1):84. PubMed ID: 34930382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies.
    Arai T; Mackenzie IR; Hasegawa M; Nonoka T; Niizato K; Tsuchiya K; Iritani S; Onaya M; Akiyama H
    Acta Neuropathol; 2009 Feb; 117(2):125-36. PubMed ID: 19139911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer's disease and frontotemporal lobar degeneration.
    Foulds P; McAuley E; Gibbons L; Davidson Y; Pickering-Brown SM; Neary D; Snowden JS; Allsop D; Mann DM
    Acta Neuropathol; 2008 Aug; 116(2):141-6. PubMed ID: 18506455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TDP-43 interacts with amyloid-β, inhibits fibrillization, and worsens pathology in a model of Alzheimer's disease.
    Shih YH; Tu LH; Chang TY; Ganesan K; Chang WW; Chang PS; Fang YS; Lin YT; Jin LW; Chen YR
    Nat Commun; 2020 Nov; 11(1):5950. PubMed ID: 33230138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of Aβ-dependent and independent pathways on TDP-43 proteinopathy in Alzheimer's disease: a possible connection to LATE-NC.
    Jamerlan A; An SSA
    Neurobiol Aging; 2020 Nov; 95():161-167. PubMed ID: 32814257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorylation-dependent TDP-43 antibody detects intraneuronal dot-like structures showing morphological characters of granulovacuolar degeneration.
    Kadokura A; Yamazaki T; Kakuda S; Makioka K; Lemere CA; Fujita Y; Takatama M; Okamoto K
    Neurosci Lett; 2009 Sep; 463(1):87-92. PubMed ID: 19539703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tau and TDP-43 synergy: a novel therapeutic target for sporadic late-onset Alzheimer's disease.
    Latimer CS; Liachko NF
    Geroscience; 2021 Aug; 43(4):1627-1634. PubMed ID: 34185246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TAR DNA-binding protein 43 in neurodegenerative disease.
    Chen-Plotkin AS; Lee VM; Trojanowski JQ
    Nat Rev Neurol; 2010 Apr; 6(4):211-20. PubMed ID: 20234357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TDP-43 proteinopathies: neurodegenerative protein misfolding diseases without amyloidosis.
    Kwong LK; Uryu K; Trojanowski JQ; Lee VM
    Neurosignals; 2008; 16(1):41-51. PubMed ID: 18097159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accumulation of transactive response DNA binding protein 43 in mild cognitive impairment and Alzheimer disease.
    Tremblay C; St-Amour I; Schneider J; Bennett DA; Calon F
    J Neuropathol Exp Neurol; 2011 Sep; 70(9):788-98. PubMed ID: 21865887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of TARDBP to Alzheimer's disease genetic etiology.
    Brouwers N; Bettens K; Gijselinck I; Engelborghs S; Pickut BA; Van Miegroet H; Montoya AG; Mattheijssens M; Peeters K; De Deyn PP; Cruts M; Sleegers K; Van Broeckhoven C
    J Alzheimers Dis; 2010; 21(2):423-30. PubMed ID: 20555136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TDP-43: an emerging new player in neurodegenerative diseases.
    Wang IF; Wu LS; Shen CK
    Trends Mol Med; 2008 Nov; 14(11):479-85. PubMed ID: 18929508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.